Answers are grounded in this paper and cite their sources.
Neoagarooligosaccharides (NAO), polysaccharides derived from seaweed, exhibit anti-obesity, hepatoprotective, and anti-inflammatory properties. However, their effects on non-alcoholic fatty liver disease (NAFLD) remain underexplored. This study investigates the impact of NAO on lipid accumulation and oxidative stress in free fatty acid (FFA)-treated HepG2 cells and high-fat diet-fed mice. NAO treatment significantly reduced triglyceride and total cholesterol levels, inhibited lipid accumulation (assessed via Oil Red O staining), and lowered liver enzyme levels. NAO also suppressed oxidative stress by enhancing antioxidant enzyme activity and reducing malondialdehyde levels. Real-time PCR and Western blot analyses revealed that NAO modulated lipid transporters, increased AMPK and β-oxidation, and reduced de novo lipogenesis. It also regulated the PI3K/AKT/Nrf2 pathway, suggesting its role in antioxidant defense. These findings highlight NAO's potential as a promising natural compound for developing effective and less toxic therapeutic interventions for NAFLD by mitigating lipid accumulation and oxidative stress. • NAO composes neoagarotetraose (DP4) and neoagarohexaose (DP6) • NAO ameliorates lipid accumulation in liver cells • NAO regulates lipogenesis and β-oxidation in cell and mouse model • NAO significantly inhibits oxidative stress via stabilization of Nrf2 and antioxidant system
No takes yet. Share an insight, caveat, or question.
Bae et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: